ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
License Agreement for TLANDO® Franchise in the U.S. and Canada
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 274082" data-attributes="member: 13851"><p>This is great news for Canadians!</p><p></p><p>TLANDO XR (testosterone tridecanoate) is coming!</p><p></p><p></p><p><em><strong>*Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which <u>Verity Pharma will market TLANDO® in the United States and, if approved, in Canada</u>.</strong> <strong>TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration. <u>The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next-generation, once-daily oral product candidate for TRT</u>.</strong></em></p><p></p><p></p><p></p><p><strong>About TLANDO XR</strong></p><p></p><p><em><strong>*TLANDO XR (also known as LPCN 1111) is a <u>next-generation, novel ester prodrug of testosterone comprised of testosterone tridecanoate (TT) which uses Lipocine's proprietary delivery technology to enhance solubility and improve systemic absorption</u>.</strong> <strong>Lipocine has successfully completed a Phase 2b dose-finding study in hypogonadal men. Results suggested that the primary objectives were met, including i<u>dentifying the dose expected to be tested in a planned Phase 3 study that would be required for FDA approval</u>.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 274082, member: 13851"] This is great news for Canadians! TLANDO XR (testosterone tridecanoate) is coming! [I][B]*Gordon Silver Limited and Verity Pharmaceuticals, Inc. (Verity Pharma) today announced that they have entered into an exclusive licensing agreement under which [U]Verity Pharma will market TLANDO® in the United States and, if approved, in Canada[/U].[/B] [B]TLANDO is the first and only oral testosterone replacement therapy (TRT) option approved by the US Food and Drug Administration (FDA) that does not require dose titration. [U]The agreement also provides Verity Pharma with the U.S. and Canadian rights to develop and commercialize LPCN 1111 (TLANDO XR), a next-generation, once-daily oral product candidate for TRT[/U].[/B][/I] [B]About TLANDO XR[/B] [I][B]*TLANDO XR (also known as LPCN 1111) is a [U]next-generation, novel ester prodrug of testosterone comprised of testosterone tridecanoate (TT) which uses Lipocine's proprietary delivery technology to enhance solubility and improve systemic absorption[/U].[/B] [B]Lipocine has successfully completed a Phase 2b dose-finding study in hypogonadal men. Results suggested that the primary objectives were met, including i[U]dentifying the dose expected to be tested in a planned Phase 3 study that would be required for FDA approval[/U].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
License Agreement for TLANDO® Franchise in the U.S. and Canada
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top